Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

180,435 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of second-line apatinib plus irinotecan as a treatment for advanced gastric adenocarcinoma or gastroesophageal conjunction adenocarcinoma: a prospective, multicenter phase II trial.
Qu J, He X, Luo Y, Yu P, Chen Y, Liu J, Wang X, Wang C, Liang T, Bai Y, Han Y, Man L, Leng C, Zhou C, He L, Wang X, Liu Y, Qu X. Qu J, et al. Among authors: chen y. Front Oncol. 2023 Apr 24;13:1072943. doi: 10.3389/fonc.2023.1072943. eCollection 2023. Front Oncol. 2023. PMID: 37168383 Free PMC article.
The activity and immune dynamics of PD-1 inhibition on high-risk pulmonary ground glass opacity lesions: insights from a single-arm, phase II trial.
Cheng B, Li C, Li J, Gong L, Liang P, Chen Y, Zhan S, Xiong S, Zhong R, Liang H, Feng Y, Wang R, Wang H, Zheng H, Liu J, Zhou C, Shao W, Qiu Y, Sun J, Xie Z, Liang Z, Yang C, Cai X, Su C, Wang W, He J, Liang W. Cheng B, et al. Among authors: chen y. Signal Transduct Target Ther. 2024 Apr 19;9(1):93. doi: 10.1038/s41392-024-01799-z. Signal Transduct Target Ther. 2024. PMID: 38637495 Free PMC article. Clinical Trial.
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis.
Zhao Y, He Y, Wang W, Cai Q, Ge F, Chen Z, Zheng J, Zhang Y, Deng H, Chen Y, Lao S, Liang H, Liang W, He J. Zhao Y, et al. Among authors: chen z, chen y. Lancet Oncol. 2024 Oct;25(10):1347-1356. doi: 10.1016/S1470-2045(24)00379-6. Epub 2024 Aug 16. Lancet Oncol. 2024. PMID: 39159630
C-reactive protein and lactate dehydrogenase serum levels potentially predict the response to checkpoint inhibitors in patients with advanced non-small cell lung cancer.
Wei Y, Xu J, Huang X, Xie S, Lin P, Wang C, Guo Y, Zou S, Zhao Z, Wen W, Song Y, Bao Z, Zhang L, Liu W, Kong W, Wang W, He B, Zhang S, Zhou C, Chen Y, Yu Z. Wei Y, et al. Among authors: chen y. J Thorac Dis. 2023 Apr 28;15(4):1892-1900. doi: 10.21037/jtd-23-240. Epub 2023 Apr 17. J Thorac Dis. 2023. PMID: 37197527 Free PMC article.
180,435 results
You have reached the last available page of results. Please see the User Guide for more information.